Skip to main content
. 2013 Sep 16;2(9):e70. doi: 10.1038/oncsis.2013.30

Figure 7.

Figure 7

TCL1b-based inhibitor ‘TCL1b-Akt-in' inhibited cell growth in human and mouse sarcoma cells. (a and b) Growth potentials of ISO-S1 (mouse angiosarcoma) and J774.1 (mouse reticulum cell sarcoma) were assessed by using Electric Cell-Substrate Impedance Sensing (ECIS Zθ Applied Biophysics). J774.1 and ISO-HAS-B-cell lines were seeded in 8WCP cell-proliferation plates with 50 μM of TAT-TCL1b-Akt-in peptide or TAT-FLAG as a control. (c and d) Growth potentials of ISO-S1 (mouse angiosarcoma) and J774.1 (mouse reticulum cell sarcoma) were assessed by trypan blue staining and by counting the cell numbers under microscopy. For this purpose, ISO-S1 (1 × 104 cells) and J774.1 cells (5 × 104 cells) were seeded in 24-well plates with 50 μM of TAT-FLAG (control) or TAT-TCL1b-Akt-in peptide. Cells were counted using trypan blue dye exclusion method at 24 and 48 h after peptide treatment.